The results of these studies have several important implications for the early diagnosis and treatment (i.e., ‘window of opportunity’) of RA patients, especially in those who are seronegative for ACPA and/or RF [18,19]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.